Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles

HIGHLIGHTS

• who: Marika Doucet and colleagues from the Department of Physiology, Anatomy and Genetics, University of Oxford, South Parks Road, Oxford, United (RIA), University of Bern, Switzerland have published the paper: Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles, in the Journal: PLOS ONE | https://doi.org/10.1371/journal.pone [0181844]. August 10, 2017 of /1371/
• what: The authors propose a novel vaccine based on the RNA bacteriophage (Qbeta) virus-like particle conjugated with short peptides of human a-syn. This approach has already been successfully applied preclinically in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.